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Nishitha Reddy, Bipin N. SavaniTransformed non-Hodgkin lymphoma (TL) arising from follicular lymphoma carries a poor prognosis, and the
median survival time after transformation is approximately 10 to 12 months. Standard chemotherapy and
radioimmunotherapy have offered promising responses; however, the duration of response does not appear
to last long. Several studies evaluating the role of autologous stem cell transplantation (auto-SCT) as a salvage
regimen have been reported, and a subset of patients benefit from this modality of treatment. With an
improvement in supportive care, outcome after allogeneic stem cell transplantation (allo-SCT) has been
improved significantly over past decades; however, very limited data are available for TL. In the era of emerg-
ing novel therapies, the actual timing, optimal conditioning regimens, and long-term impact of the type of
stem cell transplantation (auto-SCT vs allo-SCT) is unclear. This review addresses the approaches to the
management of patients with TL.
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RadioimmunotherapyINTRODUCTION
A diagnosis of follicular low-grade [1,2] lymphoma
followed by transformation to an intermediate (diffuse
large B cell, DLBCL) or an aggressive (Burkitt)
lymphoma is referred to as transformed lymphoma
(TL). Progression from follicular lymphoma (FL)
grade 1 or 2 to FL grade 3 is not considered as
transformation; progression from FL grade 3 to
a frank DLBCL is often considered TL [1,2].
Occasionally, there is a synchronous presentation
of diffuse large cell with a follicular component
in the lymph node specimen or a metachronous
presentation of an aggressive lymphoma in 1 lymphHematology and Stem Cell Transplantation Section,
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[1]. The incidence varies from 17% to 70%. Most of
these studies were conducted in the prerituximab
era; the true incidence of transformation in the era
of monoclonal antibody therapy is unknown. The
prognosis for TL is generally poor, with rapid pro-
gression of the disease. The median survival after
transformation is about 1 year, thus accounting for
a higher proportion of deaths in patients with FL.
The Follicular Lymphoma International Prognostic
Index and the histological subtype (grade 3) are im-
portant predictors of transformation in FL [2-5].
Disease-free survival (DFS) in TL treated with
standard chemotherapy is shorter compared with de
novo DLBCL. Young patients with limited stage
chemo-sensitive disease experience prolonged sur-
vival. This group, however, accounts for\20% of all
TL. High overall response rates, ranging from 50%
to 80%, with an acceptable safety were reported in
patients who were treated with ibritumomab, tositu-
momab, or rituximab therapy [6].
There is a paucity of literature on the treatment of
TL; therefore, deciding on the optimal evidence-based
treatment is a challenge. We are unaware of any pro-
spective trials exclusively for TL. The most specific
publications report on autologous stem cell transplan-
tation (auto-SCT) showed encouraging results [7].
However, these series are highly selected groups of1265
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with TL are likely to be too old, with poor perfor-
mance status or have had an insufficient response to
reinduction chemotherapy, making them ineligible
for SCT. Successful results have been reported in
selected patient populations who have achieved long-
term DFS after allogeneic (allo)-SCT. Interpretations
of these data are limited by small sample sizes and
study patients spanned over 1 to 2 decades. Non-
allo-SCT treatment options are limited by high
relapse rate and short DFS. Allo-SCT is safer than
ever, and it is possible that a novel immunomodulatory
reduced-intensity conditioning (RIC) regimen might
provide a high cure rate in this otherwise fatal lym-
phoid malignancy.
In this review, we discuss the available treatment
modalities and their incorporation into management
to improve outcome in patients with transformation
of FL to DLBCL.
BIOLOGICAL MECHANISM OF
TRANSFORMATION
The underlying biology of transformation is not
fully understood.Gene expressionprofilingof 20paired
samples of FL and TL performed by Davies et al. [8]
noted 2 pathways by which TL may evolve. One is via
a similar proliferation rate as that of the preceding FL
and the other set overexpressed genes is associated
with proliferation signatures, suggesting that an ac-
quired high proliferation rate underlies transformation.
The acquisition of novel mutations via somatic hyper-
mutations has also been implicated in the pathogenesis
of TL [8-12]. Importantly, it has been suggested that
the tumor microenvironment may play a crucial role
in transformation. In a study by Glas et al. [13], gene
expression profiling (GEP) signatures were performed
on FL samples of patients who later had transforma-
tion or had no subsequent transformation. The
GEP of patient samples who did not transform had
a down-regulation of the immune related genes,
therefore implying that the transformation may be
mediated by an ‘‘immune signature.’’ There was also
an over-expression of CD69, which is an activated
Tcellmarker in samples thatweredestined to transform.
Also, perifollicular localization of regulatory T cell
(Tregs), number of Tregs, and T cells expressing low
numbers of programmed cell death-1 proteinwere asso-
ciatedwith increased riskof transformation [14-16].The
exact mechanism as to how the microenvironment
contributes to transformation has not been studied.OUTCOME OF EARLY VERSUS LATE
TRANSFORMATION
In most cases, the transformation occurs in pa-
tients with a history of indolent lymphoma. Likewise,histologic transformation may be the first manifesta-
tion of lymphoma without a prior history of indolent
lymphoma. Compared with de novo DLBCL, TL at
diagnosis has similar overall survival (OS) but lower
complete response rates to initial therapy, and more
than one-half of these patients have continuous risk
of indolent relapse. At time of indolent relapse, sal-
vage treatment elicits new objective response in about
one-half of the cases eventually accounting for the
similar OS of TL and DLBCL.
In a French study, a matched control analysis of 60
patients with TL at diagnosis was compared with de
novo patients with DLBCL. Among patients achieving
a complete or a partial response to initial therapy, 42%
and 50% of patients underwent high-dose therapy
followed by auto-SCT, respectively. Of these, 41%
relapsed with low-grade histology. The 5-year OS
was similar between the 2 groups (62% vs 57%,
respectively). The 50-year freedom-from-progression
(FFP) rate was significantly decreased in TL compared
with de novo DLBCL (57% vs 33%, respectively;
P5 .03) [17]. It is possible that high-dose chemother-
apy upfront in patients with TL improved the FFP and
OS rates. There are no studies comparing patients
with TL at the time of diagnosis versus those with
transformation that has occurred several years after
a diagnosis of FL. Friedberg et al. [18] reported that
patients who underwent a transformation within 18
months of their diagnoses of indolent lymphoma had
improvedOS after auto-SCT compared with TL diag-
nosed after 18 months of initial diagnoses of indolent
lymphoma.
In the absence of a clinical trial, we can extrapolate
from limited available evidence (and our experience)
that patients with TL at the time of diagnosis (or early
TL) have a better prognosis compared with patients
who present with transformation several years later.
This group may therefore be considered for an aggres-
sive approach including allo-SCT incorporating
radioimmunotherapy as a part of a conditioning regi-
men or its use in the pretransplantation period to
prevent early relapses after SCT, a major cause of
treatment failure.TREATMENT MODALITIES IN
TRANSFORMED LYMPHOMA
The overall outcome for patients with TL with-
out SCT in most series is poor, with most deaths
attributed to lymphoma. Age, response to salvage
therapy, B symptoms, lactate dehydrogenase values,
bone marrow involvement, stage, no prior chemo-
therapy, and early transformation were all predictive
factors for survival after transformation [19].
The principle goal in the management of TL in
our view is to consider combined modality treatment
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consolidative therapy of curative intent with SCT,
preferably RIC allo-SCT (reducing the risk of indolent
relapse) in eligible patients (discussed below).
Chemotherapy and External Beam Radiation
Therapy in TL
Several combination chemotherapeutic agents
have shown early responses in patients with TL.
These chemotherapeutic agents have not, however,
shown a major improvement in continued responses;
the majority of patients will ultimately relapse and
pose a challenge in retreatment.
In patients with TL who have not been exposed to
an anthracycline-based regimen, rituximab-CHOP
therapy should be considered. This is based on the out-
come of patients with de novo DLBCL. The addition
of rituximab to chemotherapy improved the outcome
of patients with TL [20].
Novel alkylating agents, such as bendamustine, has
been evaluated by Friedberg and colleagues in 15 pa-
tients. In this study, 13% had a complete response/
complete response uncertain (CR/CRu) and 53% had
a partial response. The median duration of response
was 2.3 months [21]. There are no recommendations
based on evidence regarding the optimal therapy at the
time of transformation. Amajor reason for this is because
the lack of inclusion of patients with TL in clinical trials.
With the use of PET scans and its role in TL, one
may truly isolate patients with localized site of trans-
formation [22]. A Stanford study by Yeun et al. [23] re-
ported that involved field radiation therapy (IFRT)
might benefit patients with isolated nodal areas of
transformation.
Radioimmunotherapy in TL
Lymphomas are extremely sensitive to radiation
therapy. Monoclonal antibodies targeting the B cells
have clearly improved the OS. When anti-CD20
antibodies bind to surface antigens, they induce
apoptosis, antibody-dependent cellular cytotoxicity,
and complement-dependent cellular cytotoxicity of
lymphoma cells [24,25]. More recently, progress has
been made in the development of radioimmunotherapy
with anti-CD20 antibodies. The unique features of
radioimmunotherapy include the delivery of radiation
to the tumor bed and exert their direct and indirect
cytotoxic effects.
Therapy with radioimmunoconjugates has un-
dergone extensive clinical testing using murine
anti-CD20MAb conjugated to either iodine-131 or
Yttrium-90. Two radioimmunoconjugates, Yttrium-
90-labeled ibritumomab tiuxetan (beta) and iodine-
131 tositumomab (gamma), are currently approved
for the treatment of FL and have been used in TL.
Tositumomab has also been approved for TL.A phase III randomized study compared Y-90 ibri-
tumomab tiuxetan with rituximab in 143 patients with
relapsed, refractory, follicular, or transformed lym-
phoma. Patients received either a single intravenous
(i.v.) dose of Y-90 ibritumomab tiuxetan 0.4 mCi/kg
or rituximab 375 mg/m2 i.v. weekly for 4 doses. The
radioimmunotherapy group was pretreated with 2 rit-
uximab doses (250 mg/m2) to improve biodistribution
and 1 dose of indium-111 ibritumomab tiuxetan for
imaging and dosimetry. Of the 13 patients with TL,
9 patients received radioimmunotherapy. The overall
response rate was 56% (5 of 9 patients) versus 75%
in the rituximab control arm [26].
An open-label phase II study was conducted to
establish the efficacy and safety of iodine-131 tositu-
momab in recurrent TL. A single dosimetric dose
was followed at 7 to 14 days by the patient-specific
administered radioactivity required to deliver a total
body dose of 0.75 Gy. A response rate in patients
with TL was 71%. At the time this trial was reported,
in patients who attained a CR or CRu the median
duration of response was not reached [27].
An integrated efficacy analysis of the 5 clinical tri-
als of tositumomab and iodine-131 tositumomab in
patients with relapsed or refractory low-grade, FL,
or TL led to the regulatory approval of the iodine-
131 tositumomab. This report by Fisher et al., which
evaluates the role of iodine-131 tositumomab among
250 patients in 5 different clinical trials with TL, sug-
gests a potential role in a subset of patients [28-31].
Seventy-one patients (28%) were diagnosed with TL.
Of the 81 patients with time to progression .12
months, 23% had TL [32].
Ibritumomab tiuxetan as part of the conditioning
regimen has been added 14 days before an allo-SCT.
This did not interfere with the engraftment kinetics
and appears attractive as a strategy for patients with
relapsed TL [33].Auto-SCT in TL
High-dose therapy followed by auto-SCT report-
edly improves both DFS and OS for patients with
relapsed low or intermediate grade lymphoma [34-36].
This approach has therefore been investigated in
patients with TL; however, the data supporting the
efficacy of this approach for patients with TL are
limited, as most studies include only small numbers
of patients over a decade and the median follow-up of
patients in these studies are quite variable. Table 1
summarizes the results of auto-SCT in TL. Friedberg
et al. [18] reported their results on 27 patients who
underwent auto-SCT forTL. Patients who had a trans-
formation within 6 months of their diagnoses were
excluded from this study. Eleven of the 27 patients
experienced a relapse, and 4 patients developed myelo-
dysplasia or secondary acute myeloid leukemia. Twelve
Table 1. Autologous Stem Cell Transplantation Outcome in Transformed Lymphoma
Ref. Year* No. of Patients
Median
Age (Year)
No. of Regimens
Median (Range) Conditioning Regimen
Pre-SCT Disease Status
(CR+PR %) DFS/PFS (%) OS (%)
40 2011 12 47 2 (1-4) BuCy, CyTBI 91 33 (5 year) 58 (5 year)
39 2009 25 57 2 (1-11) CBV 92 59 (3 year) 64 (3 year)
42 2008 24 56 2 (1-6) BuCy, BEAM, CBV 75 33 (5 year) 52 (5 year)
38 2007 23 49.6 2 CBV, BEAM n/a 25 (5 year) 56 (5 year)
44 2001 50 40 1 (0-3) CyTBI ± VP16, BEAM or CBV CR538 30 (5 year) 51 (5 year)
37 2001 35 48 1 (0-4) VP16MelTBI 100 36 (5 year) 37 (5 year)
18 1999 27 44 3 (2-10) CyTBI CR544 46 (5 year) 58 (5 year)
43 1998 27 42 3 (1-10) CyTBI 100 n/a n/a
45 1989 10 42 n/a CyTBI, CyVP16B, CyAra-CTBI 80 n/a n/a
Ref. indicates reference number; No., number; SCT, stem cell transplantation; CR, complete remission; PR, partial remission; DFS, disease-free survival;
OS, overall survival; Cy, cyclophosphamide; VP16, etoposide; TBI, total body irradiation; BEAM, carmustine, etoposide, cytarabine, and melphalan; CBV,
cyclophosphamide, carmustine, etoposide; BuCy, busulfan, cyclophosphamide; Mel, melphalan; Ara-C, cytarabine; PFS, progression-free survival.
*Year of publication.
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months.
In another study that analyzed 35 patients who
underwent auto-SCT for TL, the 5-year OS and
progression-free survival (PFS) was 37% and 36%.
At amedian follow-up of 52months, 26%died because
of progressive disease, and 8% developed myelodys-
plasia. In the multivariate analysis, Chen et al. [37]
were able to identify only advanced age as a predictor
of survival. The median duration from diagnosis to
transformation was 3.6 years in this study. Several
other studies have presented similar results with an
auto-SCT in TL [38,39] (Table 1).
The benefit of graft purging remains unproven and
has not been practiced except in clinical trials. A long-
term follow-up study by Kasamon et al. [40] reported
phase II results of 12 patients with TL who underwent
auto-SCT with 4-hydroperoxycyclophosphamide
(4-HC) purging as part of initial or salvage therapy.
Autologous grafts derived from bone marrow harvest
were treated ex vivo with 4-HC and cryopreserved until
infusion. The preparative regimen consisted of
cyclophosphamide and total body irradiation (TBI)
(1200 cGy) or busulfan and cyclophosphamide. At ame-
dian followupof 16.6 years, only 3were event-free.Two
had nonrelapse death, and the remaining 7 patients died
of lymphomaat 0.1 to 4.3 years after bonemarrow trans-
plantation (BMT). Despite the fact that at 10 years the
OS was 50%, results should be interpreted with caution
considering a small study of highly selected patients.
Similarly, the role of purging remains controversial in
the rituximab era. A report by Andreadis et al. [41],
which used purged or unpurged cells for auto-SCT in
22 patients with TL showed that, among patients who
achieved CR before transplant, the rates of DFS,
event-free survival (EFS), and OS at 5 years were 52%,
44%, and80%respectively. Inunivariable andmultivar-
iable analysis, achievement of CR was associated with
improved outcome after auto-SCT. Similar results
were observed by the Ohio State group [42] who re-
ported their 3-year PFS and OS rate of 40% and 52%,
respectively, in 24 patients with TL after auto-SCT.The difference in outcome might be due to the
inclusion of patients with minimal disease state at the
time of transplantation.
Foran et al. [43] also showed a 5-year OS and PFS
in the range of 50% in patients younger than 60 years
at a median follow-up of 2.4 years. The median time to
transformation was 6 months. In the European Group
of Blood andMarrow Transplantation (EBMT) series,
50 patients who underwent high-dose therapy with
auto-SCT rescue for TL had 5-year OS and PFS of
51% and 30%, respectively. The median time to trans-
formation from diagnosis was 3 years. Three patients
developed secondary malignancies [44]. Schouten
et al. [45] reported their results of 10 patients undergo-
ing auto-SCT for TL in the 1980s. They report
a median overall survival of 2 months with 70% proce-
dure-related deaths. Again, interpretation of data is
limited by small studies and variable transplantation
periods, spanned over 5 to 15 years, and include
patients both in the pre- and postrituximab era.
To summarize, auto-SCT appears to play a role in
patients who present with de novo TL and appears to
be beneficial as a consolidative therapy for patients
with extensive stage disease in first complete remission
[46]. Allo-SCT options should be weighed against
auto-SCT in patients with suitable donors, especially
in patients who have received multiple prior regimens
and have had a long history of FL. Auto-SCT may not
be the best approach considering the very high relapse
rate in this group. Therefore, tandem auto-SCT fol-
lowed by safer nonablative allo-SCT is also pursued
to maintain remission.Time to Consider Early Allo-SCT in TL
With increasing use of RIC regimens, many older
patients are able to receive allo-SCT as a curative in-
tent. The hypothesis that RIC transplantations could
be used to deliver an effective graft-versus-lymphoma
(GVL) effect is true. Indeed, the typical delayed regres-
sion of malignant disease, long after any effect from
the preparative regimen has passed, is proof of the
Table 2. Allogeneic Stem Cell Transplantation Outcome in Transformed Lymphoma
Ref. Year* No. of Patients
Median
Age (Year)
No. of Regimens
Median (Range) Conditioning Regimen
Pre-SCT Disease Status
(CR+PR %) DFS/PFS (%) OS (%)
51 2010 19 57 2 (1-4) FluBu 100 68 (4 year) 68 (4 year)
53 2009 5 47 4 (3-6) BuCy 80 80 (5 year) 100 (5 year)
54 2008 25 44 3 (1-4) Cy/TBI VP-16+Cy/TBI 60 25 (3 year) 48 (3 year)
52 2009 18 46 5 (2-7) Campath, Flu, Mel (RIC) 83 55 (4 year) 54 (4 year)
50 2008 16 54 6 (1-19) FluTBI200 63 18 (3 year) 21 (3 year)
55 2008 8 57 N/A BuCy, FluBuATG 62 56 (4 year) 66 (4 year)
49 2005 16 40 2 CyVP16TBI 87 38 (5 year)
Ref. indicates reference number; No., number; SCT, stem cell transplantation; CR, complete remission; PR, partial remission; DFS, disease-free survival;
OS, overall survival; Flu, fludarabine; Mel, melphalan; RIC, reduced-intensity conditioning; TBI, total body irradiation; 200, 200 cGY; VP16, etoposide; Cy,
cyclophosphamide; Bu, busulfan; PFS, progression-free survival; EFS, event-free survival.
*Year of publication.
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curative alloresponses against the recipient’s malig-
nancy [47,48].
Given the high relapse rate seen even after
auto-SCT, and the potential benefit of a GVL after
allo-SCT, many more eligible patients with NHL
including TL are receiving allo-SCT (Table 2). The
intrinsic difficulty of interpreting the wide variation
among individual study reports lies with the heteroge-
neity of the studies (single-center vs multicenter, lack
of larger prospective data), the heterogeneity of the
patients studied (in particular, whether only patients
with TL were included), the variation in the RIC
transplantation procedure itself (eg, the conditioning
regimen, GVHD prophylaxis, and stem cell source),
and the duration of follow-up.
Doocey et al. [49] reported their outcome on
16 patients who underwent allo-SCT for TL. There
were 8 deaths related to complications of the trans-
plantation. Four patients died of disease relapse, and
the remaining 4 patients were alive and free of disease
at \2 years post-SCT. The significant number of
deaths may have been related to an increased amount
of prior therapy. Therefore, it is important to opti-
mally time the allo-SCT rather than waiting for inev-
itable disease relapse. In another study by Rezvani et al.
[50], 16 patients with TL underwent RIC allo-SCT at
a median age of 54 years. Patients had either unrelated
or related donor’s stem cell sources, and the median
numbers of regimens were 6. On a univariate analysis,
increased mortality was associated with patients who
had TL. The cumulative incidence of nonrelapse
mortality (NRM) at 3 years was 42%. These patients
also experienced a high relapsed rate with a median
time to progression of 1.6 months. The 3-year PFS
and OS were 18% and 21%, respectively.
Clavert et al. [51] reported data on RIC allo-SCT
in relapsed aggressive B cell lymphoma in an attempt
to reduce transplant-related mortality (TRM); 15 of
19 patients had TL. Of the entire group, 3 patients
were documented with disease progression, whereas
4 were not evaluable because of early death. In the
auto-allo-SCT tandem approach, the overall survivalat 4 years was 70%. In the auto-SCT followed by the
allo-SCT nontandem approach, the OS was 66% at
4 years. In this study, it is possible that auto-SCT pro-
vided the tumor control initially until the immune
GVL took effect. In another report by Thomson
et al. [52] about RIC allo-SCT among 18 patients,
the 4-year OS was 60%. In this study, 6 of the 7 relapse
events occurred in the first 10 months of RIC
allo-SCT.
Hamadani et al. discussed the role of allo-SCT for
patients with relapsed chemorefractory aggressive
B cell lymphoma. Among 5 patients with TL, 4 had
stable disease and 1 patient had progressive disease at
the time of transplantation; the 5-year OS was re-
ported to be 100% [53]. It is noteworthy, however,
that albeit a small number, a group of chemorefractory
patients can be salvaged with allo-SCT [54,55].
Historically, the limitation of allo-SCT has been
TRM. In order to offer the curative allo-SCT treatment
option for most patients, safer regimens with acceptable
graft-versus-host disease (GVHD)-associated morbidity
and TRM are preferred. Among several RIC regimens,
fludarabine, cyclophosphamide, and rituximab (FCR),
a nonablative conditioning regimen followed by either
related or unrelated donor allo-SCT is reportedly very
safe and effective in B cell lymphoid malignances. A re-
cently published MDACC study showed excellent PS
and OS (85% and 83%, respectively, after a median
follow-up of 60 months) for relapsed FL after FCR
RIC allo-SCT. The incidence of grade II-IV acute
GVHD (aGVHD) was only 11% [56].
We have also observed the safety of the FCR
regimen at our institution in patients with B cell non-
Hodgkin lymphoma (NHL), with minimal GVHD
andTRMcomparedwith other RIC regimens. In addi-
tion to the benefits of decreasing risk of GVHD and
better disease control in patients with B cell malignan-
cies, one would expect lower Epstein-Barr virus (EBV)
reactivation and posttransplantation lymphoprolifera-
tive disorders after this regimen [57,58]. There is an
almost universal consensus that chemosensitivity and
disease control before allo-SCT is very important in
the prevention of early relapse, which is a major cause
1270 Biol Blood Marrow Transplant 17:1265-1272, 2011N. Reddy and B. N. Savaniof treatment failure in TL. Incorporating novel radio-
immunotherapy as part of a conditioning regimen
might be a very attractive option before a nonablative
FCR conditioning regimen to prevent early relapse.
In this era, a stem cell source can be found for virtually
all patients who have an indication to receive allo-SCT.
RIC haploidentical-related donor or cord blood trans-
plantations (CBT) have emerged as alternatives to fill
the gap for those patients who do not have a matched
related donor (MRD) or an unrelated donor (URD),
and the outcome of these types of transplantations are
expected to be better than chemotherapy alone or
even better than auto-SCT for selected high-risk
heavily pretreated TL. The individual transplantation
center experience usingURDCBT, and haploidentical
transplantation should also be taken into consideration.
Enrollment in clinical trials should be encouraged.Pretransplantation Radioimmunotherapy
Radioimmunotherapy has been integrated with
a transplant conditioning regimen [59]. The maximally
tolerated dose of single agent 131I-tositumomab fol-
lowed by auto-SCTwas found to be 27Gy to the critical
normal organ receiving the greatest radiation. Cardio-
pulmonary toxicity was noted at higher doses. This
strategy helped deliver 10 times the radiation dose to
the tumor as compared with the whole body and twice
the radiation dose delivered as to the vital organs such
as the lungs. With this approach, the nonhematopoietic
toxicities were low. The overall response rate was 95%
with 84% complete responses [60]. In a multivariable
cohort analysis of 125 patients, in relapsed refractory
FL,myeloablative 131I-tositumomab followed by ASCT
was compared with conventional high-dose therapy
followed by auto-SCT. The 5-year PFS was 48% for
the high-dose radioimmunotherapy group and 29%
for the high-dose therapy by auto-SCTgroup (P5 .03).
Interestingly, there was no evidence of increased myelo-
dysplastic syndrome at an 8-year follow-up [61].
Other investigators have evaluated the use of esca-
lating the dose of 90Y-ibritumomab tiuxetan in combi-
nation with chemotherapy and auto-SCT. Winter
et al. [62] escalated the dose of Zevalin beyond 0.5
mCi/kg, along with high-dose carmustine (BCNU),
etoposide, cytarabine, and melphalan (BEAM regi-
men) and auto-SCT, and found 3-year PFS and OS
rates of 43% and 63%, respectively, in a heavily pre-
treated group of 33 patients with relapsed and refrac-
tory lymphoma.
Vose et al. [63] evaluated radioimmunotherapy in
a phase II trial among 40 patients withDLBCL. A total
0.75 Gy whole-body dose of Bexxar was administered
7 days before initiating full-dose BEAM chemotherapy
and 12 days before auto-SCT with no appreciable in-
crease in toxicities. This regimen yielded an estimated
3-year PFS of 70% and OS of 81%.For patients in whom a nonablative transplantation
is preferred, radioimmunotherapy can be employed to
provide cytoreduction to safely induce disease control
while minimizing nonhematologic toxicity. The
allo-SCT could maintain the remissions via the GVL
effect and reconstitute hematopoiesis [36]. Using
this approach, 16 patients with relapsed CD201 lym-
phoma, of which 15 patients were chemotherapy
resistant, underwent therapy with 0.4 mCi/kg Y-90
ibritumomab tiuxetan followed by fludarabine and
2 Gy TBI and matched allo-SCT. At day 28, 7 of
16 patients demonstrated responses [64]. Khouri
et al. [65] reported a feasibility study using escalated
doses of 90Y-ibritumomab tiuxetan before cyclophos-
phamide, fludarabine, rituximab, and allo-SCT in
7 patients with relapsed B cell NHL. Although longer
follow-up on outcome and toxicities are needed, it
is clear that such approaches need to be urgently
considered for TL.SUMMARY
Patients with early TL appear to have a better
prognosis than late TL. Several factors may affect
the natural history of FL that undergoes transforma-
tion. It would be of interest to be able to identify pa-
tients based on either the tumor microenvironment
or their gene expression profiling, instead of patients
who are destined to undergo transformation. Multiple
treatment approaches, resistance mechanisms inherent
to the tumor, or alteration of the tumor microenviron-
ment may play a role in such transformation. In the
rituximab era, with the increased use of maintenance
strategies, the true incidence of such transformation
is unknown. In the PET era, it is possible that transfor-
mation to an aggressive phenotype is identified early
along with the clinical features that are suggestive
of transformation and therefore affect prognosis and
early treatment decisions. Novel targeted agents cur-
rently in clinical trials may change the treatment
paradigm in the future.
Treatment modality with radioimmunotherapy
appears promising; however, response duration is short
lived. We believe prior radioimmunotherapy or incor-
porating it as a part of RIC allo-SCTmight be an attrac-
tive option to prevent early relapse before GVL takes
over disease control. Allo-SCT should be considered
early for those patients who have received 2 or more
therapies, including an anthracycline for FL when a re-
lated or an unrelated donor is available. Alternate stem
cell source using cord blood or a haploidentical related
donor also needs to be considered. Tandem auto-SCT
followed by allo-SCT needs to be explored in selected
patients with early good results in a small series.
Considering the limited data available in patients
with TL, larger studies are needed. This should
Biol Blood Marrow Transplant 17:1265-1272, 2011 1271Stem Cell Transplantation in Transformed Lymphomainclude analysis of registry data to the evaluate out-
come of TL in the rituximab era after SCT (auto or
allo).We also recommend early referral to a transplant
center to explore the most effective SCT option and,
if available, to be enrolled in a clinical trial.ACKNOWLEDGMENTS
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